Loading...
CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis
Triple-negative breast cancer (TNBC) has a poor prognosis due to the lack of specific therapeutic targets. CCT020312, a selective eukaryotic translation initiation factor 2 alpha (eIF2α)/protein kinase RNA-like endoplasmic reticulum kinase (PERK) activator, may have a potent anti-tumor effect. In th...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7250150/ https://ncbi.nlm.nih.gov/pubmed/32508655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00737 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|